HC Wainwright reissued their buy rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) in a report issued on Friday morning, Benzinga reports. HC Wainwright currently has a $15.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q1 2023 earnings at ($0.30) EPS.
Other equities research analysts have also recently issued reports about the stock. Citigroup raised their price objective on shares of Aldeyra Therapeutics from $23.00 to $28.00 in a research report on Friday. StockNews.com upgraded shares of Aldeyra Therapeutics from a sell rating to a hold rating in a report on Monday, November 14th.
Aldeyra Therapeutics Stock Down 2.2 %
Shares of NASDAQ:ALDX opened at $7.02 on Friday. Aldeyra Therapeutics has a 52-week low of $2.36 and a 52-week high of $8.00. The stock has a market cap of $411.09 million, a P/E ratio of -6.62 and a beta of 1.07. The business has a fifty day moving average of $6.65 and a two-hundred day moving average of $6.17. The company has a quick ratio of 11.78, a current ratio of 11.78 and a debt-to-equity ratio of 0.10.
Hedge Funds Weigh In On Aldeyra Therapeutics
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
- Get a free copy of the StockNews.com research report on Aldeyra Therapeutics (ALDX)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.